Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alclofenac is a nonsteroidal anti-inflammatory drug (NSAID) indicated primarily for the treatment of rheumatologic conditions such as rheumatoid arthritis, ankylosing spondylitis, and as an analgesic in painful arthritic pathologies. Its mechanism of action involves inhibition of prostaglandin G/H synthase 2 through reversible blockade of the cyclooxygenase (COX) enzyme, thereby preventing the production of inflammatory mediators like prostacyclins and prostaglandins. This results in reduced inflammation and pain[1]. Alclofenac is absorbed irregularly from the gastrointestinal tract, with maximum plasma concentrations reached within 1–4 hours after oral or rectal administration. It exhibits high protein binding (90–99%) and has a volume of distribution of 0.1 L/kg[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alclofenac.